纳米药物设计与负责任创新：建构论视角的解释

The Design of Nano-drug and Responsible Innovation: The Interpretation from Constructivism Perspective

摘要:

药物设计是药品生命周期的起始阶段,也是控制药品风险的关键环节。纳米药物设计是实现风险控制的“源头”治理,设计过程采用的价值敏感设计(价值嵌入)方法是设计者负责任创新意识的展现。由纳米制剂的结构效应和尺寸效应客观决定的纳米药物设计者责任不仅表现为对纳米药物风险的技术评估(TA)的责任,而且需要从建构论视角探索纳米药物风险的建构性技术评估(CTA)体系。建构性纳米药物风险评估的理论基础是马克思主义的“人本”理论和利益相关者理论。纳米药物设计者实施负责任创新的路径应关注知识提升、道德规范、法律制约及政策导向四个维度。

Abstract:

the design of drug is the initial stage of life cycle of a drug, and it is also a key link to control the risk of drug. The design of Nano-drug will be to realize the risk control of the "origin the method of value sensitive design used to design process showed the consciousness of responsible innovation of designers. The responsibility of designers objectively caused by the structure effect and size effect of nano-preparation not only includes the responsibility of the technical assessment (TA) related to risk of nano-drug, and but also need to study a system of constructive technology assessment (CTA) linking with risk from the constructivism perspective. The theory basis for constructing risk assessment of nano-drug is the humanism theory of Marxism and stakeholder theory. The designers of nano-drug implement the path of responsible innovation should pay attention to promotion of knowledge, codes of ethics, legal constraints and policy orientation in four dimensions.